ArticleClinical and molecular hepatology2025
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".
Sun Young Yim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.